Astellas Pharma Inc (ALPMY)

$10.59 -0.12 (-1.10%)
Market Cap 19.38B
Revenue (ttm) 12.62B
Net Income (ttm) 334.93M
EPS (ttm) N/A
PE Ratio 9.73
Forward PE 15.07
Profit Margin 2.65%
Debt to Equity Ratio 0.60
Volume 238,100
Avg Vol 115,034
Day's Range N/A - N/A
Shares Out 1.81B
Stochastic %K 59%
Beta 0.25
Analysts Sell
Price Target $14.10

Company Profile

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 81 3 3244 3000
Address:
2-5-1, Nihonbashi-Honcho, Chuo, Japan
Quantumup
Quantumup Oct. 20 at 8:30 PM
Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:
0 · Reply
Quantumup
Quantumup Oct. 13 at 3:36 PM
Citizens reiterated $TSHA Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. $NGNE $ACAD $ALPMY Citizens JMP added: A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett gene therapy competitor. We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: Overall, both TSHA & NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. Based on the more involved procedure required for ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.
0 · Reply
Quantumup
Quantumup Sep. 12 at 11:47 AM
Citizens reiterated $TSHA Market Outperform-$6 and said, Taysha Gene Therapies is developing TSHA-102 for Rett Syndrome with remarkable impact on developmental milestones. $ALPMY Citizens added:
0 · Reply
Quantumup
Quantumup Aug. 1 at 1:06 PM
Cantor⬆️ $APLS PT to $40 from $39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well. $NVS AZN $ALPMY $OCUL $EYPT REGN SRZN RHHBY Cantor said in its note: "We reiterate Overweight rating on $APLS as GA market is stabilizing and the launch in C3G/IC-MPGN is under way. C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting "FaCtOr B" (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta's label. Consequently, we think Empaveli C3G launch will go well."
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 8:26 PM
$TNXP $REPL $GSK $ALPMY
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 7:27 PM
$TNXP brother the 52 week high is $130 from when the FDA decided we don’t need an advisory panel. $44.85 is not the ceiling. We’re buying at a third of the ceiling and once approved this should be smashing that $130 level. Trying not to spam the board but this has much more upside than $REPL or $GSK or $ALPMY with their PDUFAs looming in July 🚀
1 · Reply
Quantumup
Quantumup Jul. 10 at 7:51 PM
Cantor reiterated $APLS Overweight/$39 after competitor $ALPMY reported preliminary IZERVAY™ figures. $OCUL $EYPT REGN $SRZN RHHBY William Blair reiterated $APLS at an Outperform rating after competitor $ALPMY hosted a business update call to provide a U.S. commercial update on Izervay. Both Seem to Question #s Cantor and William Blair said in their notes to investors:
2 · Reply
Quantumup
Quantumup Jul. 8 at 12:26 PM
Ladenburg Thalmann🏁 $ORIC Buy-$15. $PFE $ALPMY $AMGN $TNGX Ladenburg Thalmann said in its research report: "Initiating coverage of $ORIC with a Buy rating and $15 price target based on 1) emerging profile of the PRC2 inhibitor ORIC-944 as a potential fast-follower to mevrometostat in treatment AR-experienced mCRPC, 2) strategic pivot for development of ORIC-114 from 2nd-line exon 20 EGFR/HER2 tumors to the 1st-line representing a larger addressable population and opportunity to maximize clinical differentiation based on potential best-in-class CNS activity and 3) experienced management team with a track record of guiding targeted cancer drugs through clinical development."
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:28 AM
$ALPMY Astellas Pharma enters license agreement with Evopoint Biosciences for XNW27011 Astellas Pharma and Evopoint Biosciences announced they have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate targeting CLDN18.2. The agreement grants Astellas a worldwide (excluding China's mainland, Hong Kong, Macao and Taiwan region) exclusive license to develop and commercialize XNW27011. XNW27011 is currently being evaluated in a Phase 1/2 study in China in patients with CLDN18.2-expressing solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer. It uses a proprietary topoisomerase I inhibitor payload and linker technology, an approach that has demonstrated clinical success in other approved cancer therapies. Under the terms of the agreement, Evopoint will receive a $130M upfront payment and is eligible to receive up to $70M near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34B, as well as royalties on net sales of XNW27011, if approved.
0 · Reply
Quantumup
Quantumup May. 20 at 7:30 PM
JPMorgan reiterated $ORIC Overweight-$20-Focus List and said, "We see a very low probability for a downside scenario, being driven by mixed efficacy and / or mixed safety," in its scenario analysis. $PFE $ALPMY #ASCO25 JPMorgan also said it views, " $ORIC shares should be ~2-4X current levels to appropriately reflect the probability-adjusted potential of ORIC-944 alone." JPMorgan provided its Bull, Bear and Base case share price scenarios and additionally said in their research note (in Image):
0 · Reply
Latest News on ALPMY
No data available.
Quantumup
Quantumup Oct. 20 at 8:30 PM
Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:
0 · Reply
Quantumup
Quantumup Oct. 13 at 3:36 PM
Citizens reiterated $TSHA Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. $NGNE $ACAD $ALPMY Citizens JMP added: A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett gene therapy competitor. We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: Overall, both TSHA & NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. Based on the more involved procedure required for ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.
0 · Reply
Quantumup
Quantumup Sep. 12 at 11:47 AM
Citizens reiterated $TSHA Market Outperform-$6 and said, Taysha Gene Therapies is developing TSHA-102 for Rett Syndrome with remarkable impact on developmental milestones. $ALPMY Citizens added:
0 · Reply
Quantumup
Quantumup Aug. 1 at 1:06 PM
Cantor⬆️ $APLS PT to $40 from $39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well. $NVS AZN $ALPMY $OCUL $EYPT REGN SRZN RHHBY Cantor said in its note: "We reiterate Overweight rating on $APLS as GA market is stabilizing and the launch in C3G/IC-MPGN is under way. C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting "FaCtOr B" (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta's label. Consequently, we think Empaveli C3G launch will go well."
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 14 at 8:26 PM
$TNXP $REPL $GSK $ALPMY
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 7:27 PM
$TNXP brother the 52 week high is $130 from when the FDA decided we don’t need an advisory panel. $44.85 is not the ceiling. We’re buying at a third of the ceiling and once approved this should be smashing that $130 level. Trying not to spam the board but this has much more upside than $REPL or $GSK or $ALPMY with their PDUFAs looming in July 🚀
1 · Reply
Quantumup
Quantumup Jul. 10 at 7:51 PM
Cantor reiterated $APLS Overweight/$39 after competitor $ALPMY reported preliminary IZERVAY™ figures. $OCUL $EYPT REGN $SRZN RHHBY William Blair reiterated $APLS at an Outperform rating after competitor $ALPMY hosted a business update call to provide a U.S. commercial update on Izervay. Both Seem to Question #s Cantor and William Blair said in their notes to investors:
2 · Reply
Quantumup
Quantumup Jul. 8 at 12:26 PM
Ladenburg Thalmann🏁 $ORIC Buy-$15. $PFE $ALPMY $AMGN $TNGX Ladenburg Thalmann said in its research report: "Initiating coverage of $ORIC with a Buy rating and $15 price target based on 1) emerging profile of the PRC2 inhibitor ORIC-944 as a potential fast-follower to mevrometostat in treatment AR-experienced mCRPC, 2) strategic pivot for development of ORIC-114 from 2nd-line exon 20 EGFR/HER2 tumors to the 1st-line representing a larger addressable population and opportunity to maximize clinical differentiation based on potential best-in-class CNS activity and 3) experienced management team with a track record of guiding targeted cancer drugs through clinical development."
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 11:28 AM
$ALPMY Astellas Pharma enters license agreement with Evopoint Biosciences for XNW27011 Astellas Pharma and Evopoint Biosciences announced they have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate targeting CLDN18.2. The agreement grants Astellas a worldwide (excluding China's mainland, Hong Kong, Macao and Taiwan region) exclusive license to develop and commercialize XNW27011. XNW27011 is currently being evaluated in a Phase 1/2 study in China in patients with CLDN18.2-expressing solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic cancer. It uses a proprietary topoisomerase I inhibitor payload and linker technology, an approach that has demonstrated clinical success in other approved cancer therapies. Under the terms of the agreement, Evopoint will receive a $130M upfront payment and is eligible to receive up to $70M near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34B, as well as royalties on net sales of XNW27011, if approved.
0 · Reply
Quantumup
Quantumup May. 20 at 7:30 PM
JPMorgan reiterated $ORIC Overweight-$20-Focus List and said, "We see a very low probability for a downside scenario, being driven by mixed efficacy and / or mixed safety," in its scenario analysis. $PFE $ALPMY #ASCO25 JPMorgan also said it views, " $ORIC shares should be ~2-4X current levels to appropriately reflect the probability-adjusted potential of ORIC-944 alone." JPMorgan provided its Bull, Bear and Base case share price scenarios and additionally said in their research note (in Image):
0 · Reply
Quantumup
Quantumup May. 20 at 5:44 PM
Cantor Fitzgerald reiterated $ORIC at an Overweight rating after🗣️w/ $ORIC mgmt., who sounded very +VE on replicating the initial PSA response rates for ORIC-944 (PSA50 data of 50% and PSA90 of 30%+) in a larger sample size, which should show signs of efficacy differentiation vs. $PFE's (Pfizer's) mevrometostat (similar mechanism as ORIC-944), plus recent KOL feedback on ORIC-944's MoA and $PFE's mevrometostat ASCO-GU data. $ALPMY Cantor Fitzgerald said, "We would be buyers of $ORIC into this likely positive update for ORIC-944 in the coming weeks. KOL feedback on this mechanism and Pfizer's mevrometostat ASCO-GU data (rPFS HR of 0.51 and median PFS benefit of ~8 months over Xtandi) is overwhelmingly positive, which we believe is not at all priced into the stock at a $350M market cap, relative to the multiblockbuster opportunity for ORIC-944 in prostate cancer."
0 · Reply
DonCorleone77
DonCorleone77 Apr. 28 at 12:10 PM
$ATNM $SNDX $ALPMY Actinium's Actimab-A shows antileukemic activity in AML models Actinium Pharmaceuticals (ATNM) highlighted data presented at the American Association for Cancer Research Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia, or AML, models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including menin and FLT3 inhibitors and the hypomethylating agent azacitidine resulted in significant antileukemic activity in AML cells lines with FLT3, NPM1, KMT2A and TP53 mutations. Additionally, in animal models, Actimab-A significantly enhanced tumor growth inhibition, prolonged the duration of response and survival when combined with the menin inhibitor revumenib owned by Syndax Pharmaceuticals (SNDX), and potentiated AML cell killing in combination with the FLT3 inhibitor gilteritinib owned by Astellas Pharma (ALPMY) and HMA azacitidine. Actimab-A is Actinium's lead radiotherapy that delivers Actinium-225, alpha-emitter radioisotope payload that can kill targeted cells that express CD33. CD33 is expressed ubiquitously in AML and in other myeloid malignancies such as myeloid dysplastic syndromes.
0 · Reply
MakingMoneyHere
MakingMoneyHere Apr. 22 at 8:17 AM
$SGMO We are all waiting for news about Fabry, but I personally expect news from $RHHBY Genentech and $ALPMY Astellas in the near future.
0 · Reply
MakingMoneyHere
MakingMoneyHere Apr. 15 at 12:59 PM
$SGMO We look like this in their eyes $LLY $RHHBY $ALPMY
0 · Reply
Persevere_With_Patience
Persevere_With_Patience Apr. 8 at 6:31 PM
$SGMO The STAC-BBB capsid is highly novel due to its exceptional ability to cross the BBB, achieve high CNS expression, and reduce off-target effects, addressing critical limitations of traditional AAV vectors. Among its direct competitors (Capsida, Voyager, Astellas, and Dyno), STAC-BBB stands out with superior preclinical performance and strong industry backing. While clinical validation is still needed to confirm its lead, STAC-BBB currently appears to be at the forefront of CNS-targeted gene therapy delivery systems. $ALPMY $RHHBY $LLY deals wouldn't happen otherwise.
1 · Reply
MakingMoneyHere
MakingMoneyHere Apr. 8 at 9:53 AM
$SGMO I don't know, but we're sitting at 0.70 cents with a unique pipeline, two drugs in phase 3, and our partners are $LLY $RHHBY $ALPMY. This is ridiculous... 😒 😀
4 · Reply
DocPharm
DocPharm Apr. 1 at 6:14 PM
$ALPMY $ALPMF found a new 💎 to start the accumulation 📝📝📝 …Entered small position IMO - Other biotech gems/mispriced equities include: 1. another A-company 2. A-company’s parent company 3. $CVAC 4. $PFE 5. $RHHBY
0 · Reply
DocPharm
DocPharm Apr. 1 at 6:04 PM
$ALPMY interesante
0 · Reply
Quantumup
Quantumup Mar. 6 at 8:16 PM
William Blair~on 2/28~🏁 $CRBP Outperform $ALPMY ABBV $PFE $SKYE $NVO William Blair said in its initiation report: "We believe that an investment in Corbus provides investors with exposure to the rapidly expanding field of antibody-drug conjugates (ADCs) and to a target that we view as commercially validated. The ADC market has garnered significant attention in recent years, and nectin-4 as a target has been commercially validated and de-risked through the success of Padcev in bladder cancer. We believe that Corbus's lead program, CRB-701, could differentiate itself from other nectin-4-targeted ADCs through an extended half-life and improved linker stability, leading to a more convenient dosing regimen and superior efficacy and safety. Initial Phase I data support this thesis, in our view." Besides an #ADC, $CRBP also has a cannabinoid 1 (CB1) receptor inverse agonist, CRB-913, for the Tx of obesity, that I'm also interested in. There is some CB1 info in the repost/Purple Image, from WB:
0 · Reply
Quantumup
Quantumup Feb. 4 at 6:25 PM
BofA reiterated $APLS Buy; $47: 4Q Earnings Preview: Looking for potential Syfovre guidance ( ISEE - $ALPMY ( $OCUL $EYPT $REGN RHHBY)) BofA said in its note: "Apellis (APLS, Buy, $47 PO) pre-announced 4Q revenues for Syfovre of $167MN (+10% q/q) and for Empaveli of $23MN (-6% q/q). 4Q Syfovre revenues were ahead of expectations following flat growth in 3Q. The company reported 94K vials were distributed in 4Q. Management noted they continue to focus on physician and patient education highlighting Syfovre's differentiated efficacy. $APLS has underscored they now have preferred positioning in certain Medicare Advantage plans, which they expect could be a key driver of new patient adds near term. We will look for additional color on competitive dynamics in geographic atrophy (GA) at the upcoming earnings call and potential guidance for the year. Near term, we await the upcoming regulatory decision for Izervay's label with target action date of February 26th. BofA goes on to say:
2 · Reply
Quantumup
Quantumup Feb. 4 at 3:10 PM
Cantor Fitzgerald reiterated $ORIC Overweight. On upcoming mevro data: likes R/R; thinks stock could be up 50-100%, after KOL checks & investor convos. Citi Issued a 30-Day Upside Catalyst Watch on $ORIC reiterated Buy; $13 $PFE $ALPMY $OLMA #GU25 Citi and Cantor Fitzgerald said in their research reports to investors:
0 · Reply
Quantumup
Quantumup Jan. 7 at 1:17 PM
Citi🏁initiated $EYPT Buy; $33, says "the path to develop sustained-release drugs for wAMD harkens back to other heavily debated two-player races in ophthalmology that also rapidly advanced the standard-of-care (i.e. Eylea/Lucentis, Syfovre/Izervay)." $OCUL $RGEN RHHBY $APLS $ALPMY "Consistent with these precedents, we expect both $EYPT and key competitor $OCUL to capture meaningful share, but we also expect one player to eventually dominate. We obviously don't have all the answers pending Ph3 data in 4Q25 / 2026 for $OCUL/ $EYPT respectively. However, real-time field checks (~100 physician survey conducted 12/2024) suggest 1) efficacy data skew strongly to $EYPT given ~7x higher N (102 vs. 15), 2) Ph3 trial endpoints appear to skew to $OCUL, though we stress important subtleties inside, and 3) possible potency differences plus delivery/formulation nuances indicate real-world differentiation won't hinge on these transient Street debates."
1 · Reply